Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of VSA003 Injection in Chinese Adolescents and Adults With Homozygous Familial Hypercholesterolaemia (HoFH)

Next Previous
Trial Profile

A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of VSA003 Injection in Chinese Adolescents and Adults With Homozygous Familial Hypercholesterolaemia (HoFH)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 May 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zodasiran (Primary)
  • Indications Hypercholesterolaemia; Hyperlipoproteinaemia type II
  • Focus Registrational; Therapeutic Use
  • Sponsors Arrowhead Pharmaceuticals; Visirna Therapeutics

Most Recent Events

  • 05 May 2026 Status changed from not yet recruiting to active, no longer recruiting.
  • 04 Dec 2024 Status changed from planning to not yet recruiting.
  • 23 May 2023 According to an Arrowhead Pharmaceuticals Media Release, the company plans to conduct a meeting with regulatory authorities in the second half of 2023 to discuss the proposed study design of this study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top